Resonance Health (ASX:RHT) ROA %: 16.36% (As of Dec. 2025)


What is Resonance Health ROA %?

Resonance Health ASX:RHT +4.55% ROA % is 16.36% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 686 Healthcare Providers & Services companies, Resonance Health ranks better than 62.97% on this metric.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Resonance Health's annualized Net Income for the quarter that ended in Dec. 2025 was A$2.93 Mil. Resonance Health's average Total Assets over the quarter that ended in Dec. 2025 was A$17.93 Mil. Therefore, Resonance Health's annualized ROA % for the quarter that ended in Dec. 2025 was 16.36%.

The historical rank and industry rank for Resonance Health's ROA % or its related term are showing as below:

ASX:RHT' s ROA % Range Over the Past 10 Years
Min: -9.11   Med: -6.32   Max: 21.16
Current: 4.29

During the past 13 years, Resonance Health's highest ROA % was 21.16%. The lowest was -9.11%. And the median was -6.32%.

ASX:RHT's ROA % is ranked better than
62.97% of 686 companies
in the Healthcare Providers & Services industry
Industry Median: 1.75 vs ASX:RHT: 4.29

Resonance Health  (ASX:RHT) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=2.932/17.9265
=(Net Income / Revenue)*(Revenue / Total Assets)
=(2.932 / 15.95)*(15.95 / 17.9265)
=Net Margin %*Asset Turnover
=18.38 %*0.8897
=16.36 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Resonance Health ROA % Related Terms


Resonance Health ROA % Historical Data

* Premium members only.

The historical data trend for Resonance Health's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Resonance Health ROA % Chart

Resonance Health Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 -9.11 -6.36 0.95 -8.33

Resonance Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.83 8.39 -9.94 -7.78 16.36

ASX:RHT vs VEEV, BTSG, TEM: ROA % Comparison

For the Health Information Services subindustry, Resonance Health's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resonance Health ROA % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's ROA % distribution charts can be found below:

* The bar in red indicates where Resonance Health's ROA % falls into.



Resonance Health ROA % Calculation

Resonance Health's annualized ROA % for the fiscal year that ended in Jun. 2025 is calculated as:

ROA %=Net Income (A: Jun. 2025 )/( (Total Assets (A: Jun. 2024 )+Total Assets (A: Jun. 2025 ))/ count )
=-1.733/( (23.733+17.89)/ 2 )
=-1.733/20.8115
=-8.33 %

Resonance Health's annualized ROA % for the quarter that ended in Dec. 2025 is calculated as:

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=2.932/( (17.89+17.963)/ 2 )
=2.932/17.9265
=16.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2025) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of 16.36% mean?
Resonance Health (ASX:RHT) has a ROA % of 16.36% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Resonance Health and its competitors. According to the industry distribution chart, Resonance Health ranks #254 out of 686 companies in the Healthcare Providers & Services industry, placing it in the top 37%.
Is Resonance Health's ROA % too high?
Resonance Health's current ROA % is 16.36%. The Healthcare Providers & Services industry median ROA % is 1.75. Resonance Health's value of 16.36% is 834.9% above this industry median. Based on the distribution chart, Resonance Health ranks #254 out of 686 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Resonance Health's ROA % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #254 out of 686 companies for ROA %. This puts Resonance Health in the upper half of its industry. The industry median ROA % is 1.75. Resonance Health's value of 16.36% is 834.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Healthcare Providers & Services company?
The median ROA % among Healthcare Providers & Services companies is 1.75, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current ROA % of 16.36% is 834.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median ROA % is 1.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current ROA % is 16.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.05 — trading 61.7% below its estimated fair value. The current ROA % is 16.36% and 834.9% above the Healthcare Providers & Services industry median of 1.75. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current ROA % is 16.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Resonance Health Business Description

Address 141 Burswood Road, Level 1, Burswood, Perth, WA, AUS, 6100
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.